Total fish consumption and total stroke risk. Effect modification.
- For total stroke risk, stratified analysis was performed to examine the possibility that effects might differ between different levels of intake (Table 1). Four different levels of consumption were considered, relative to nonconsumption: < 1, 1, 2, and ≥ 3 servings/week. Data from 17 cohorts, including 19.971 cases could be included. Data from Bravata DM [35] could not be included because levels of intake were not clearly defined, and no RR's were provided. The protective effect became stronger with increasing levels of consumption (RR = 0.98, 0.94, 0.93, and 0.89 for < 1, 1, 2, and ≥ 3 servings/wk, respectively). Effects sizes were heavily dependent on data from one single cohort which included the majority of cases (Kinjo Y [10]). Exclusion of data from this cohort strenghtened all effect sizes (RR = 0.97, 0.89, 0.86, and 0.86 for < 1, 1, 2, and ≥ 3 servings/wk, respectively).
- For total stroke risk, analysis stratified by gender showed that (non)significant protective effects (P = < 0.10) were restricted to female cohorts (Table 2).
In addition, within-cohort comparisons (n = 5) showed that RR's were consistently lower among women. Average RR's are 0.99 for men, and 0.80 for women.
But authors from 3 other cohorts stated that effects did not differ significantly between men and women (Kinjo Y [10], Montonen J [13], Mozaffarian D [24]). - For total stroke risk, (non)significant protective effects were restricted to findings among US and Asian cohorts (Tables 3-5). Average RR's suggested possible protective effects among Asian cohorts (6 cohorts: RR = 0.87), and US cohorts (8 cohorts: RR = 0.77), but not among European cohorts (7 cohorts: RR = 0.96).
- For ischemic stroke risk, (non)significant protective effects were restricted to US cohorts (Tables 6-8). Average RR's suggested a possible protective effect among US cohorts (3 cohorts: RR = 0.57), but not among European cohorts (3 cohorts: RR = 0.92), and Asian cohorts (4 cohorts: RR = 0.98).
- For hemorrhagic stroke risk, (non)significant protective effects were restricted to findings among Asian cohorts (Tables 9-11). Average RR's suggested a possible protective effect among Asian cohorts (4 cohorts: RR = 0.87), and European cohorts (3 cohorts: RR = 0.84), but not among US cohorts (3 cohorts: RR = 1.16).
- In one cohort a significant protective effect against ischemic stroke risk was found among men with median intake (0.91-1.14 g/d) of alpha-linolenic acid only (He K [14]).
- No significant effect modification was found by intakes of vitamin E (He K [14]) or aspirin (Iso H [14], He K [14], Mozaffarian D [24]).
- No significant effect modification was found by serum cholesterol (Montonen J [13]) systolic blood pressure (Mozaffarian D [2005]), or hypertension (Montonen J [13], Mozaffarian D [24]).
- No significant effect modification was found by age (Gillum RF [17, Mozaffarian D [24]), race (Gillum RF [17]), education (Mozaffarian D [25]), rural/urban status (Kinjo Y [10]), BMI (Montonen J [13]), or smoking status (Kinjo Y [10], Mozaffarian D [24]).
| Author | Cohort name | Cases | < 1 serving/week | 1 serving/week | 2 servings/week | ≥ 3 servings/week |
|---|---|---|---|---|---|---|
| 42) Larsson SC (2011) | The Swedish Mammography Cohort | 1,680 | HR = 1 | HR = 0.91 | HR = 0.95 | HR = 0.86 |
| 38) Kaushik S (2008) | The Blue Mountains Eye Study | 69 | HR = 1 | HR = 0.51 | HR = 0.62 | HR = 0.62 |
| 36) Yamagishi K (2008) | The JACC Study | 972 | HR = 1 | HR = 1 | HR = 0.98 | HR = 0.92 |
| 34) Myint PK (2006) | The EPIC-Norfolk Study | 217 men, and 204 women | Men: RR = 1 Women: RR = 1 | Men: RR = 1.12 Women: RR = 0.74 | Men: RR = 1.12 Women: RR = 0.74 | Men: RR = 1.34 Women: RR = 0.86 |
| 32) Nakamura Y (2005) | The NIPPON DATA80 | 288 | RR = 1* | RR = 0.75 | RR = 0.75 | RR = 0.89 |
| 31) Ness AR (2005) | The Boyd Orr Cohort | 83 | RR = 0.90 | RR = 0.79 | RR = 2.01 | RR = 2.01 |
| 29) Folsom AR (2004) | The Iowa Women's Health Study | 313 | RR = 1.15 | RR = 0.95 | RR = 0.90 | RR = 1.06 |
| 27) Sauvaget C (2003) | The Hiroshima/Nagasaki Life Span Study | 1,260 | HR = 0.82 | HR = 0.82 | HR = 0.74 | HR = 0.73 |
| 24) Mozaffarian D (2005) | The Cardiovascular Health Study | 626 | HR = 0.94 | HR = 0.75 | HR = 0.75 | HR = 0.75 |
| 19) Yuan JM (2001) | The Shanghai Cohort Study | 480 | RR = 1 | RR = 1 | RR = 0.84 | RR = 0.93 |
| 17) Gillum RF (1996) | The NHANES I | 262 white men 251 white women | White men: RR = 1.27 White women: RR = 0.78 | White men: RR = 1.23 White women: RR = 0.77 | White men: RR = 0.85 White women: RR = 0.55 | White men: RR = 0.85 White women: RR = 0.55 |
| 15) Morris MC (1995) | The Physician's Health Study | 173 | RR = 1 | RR = 0.9 | RR = 0.8 | RR = 0.7 |
| 14) He K (2002) | The Health Professsional's Follow-up Study | 608 | RR = 0.87 | RR = 0.74 | RR = 0.67 | RR = 0.75 |
| 14) Iso H (2001) | The Nurses' Health Study | 574 | RR = 0.97 | RR = 0.78 | RR = 0.73 | RR = 0.61 |
| 13) Montonen J (2009) | The Finnish Mobile Clinic Health Survey | 659 | RR = 1 | RR = 1.01 | RR = 1.05 | RR = 1.04 |
| 10) Kinjo Y (1999) | No cohort name defined | 11,030 | RR = 1 | RR = 0.98 | RR = 0.98 | RR = RR = 0.92 |
| 2) Orencia AJ (1996) | The Western Electric Study | 222 | HR = 0.98 | HR = 0.98 | HR = 0.94 | HR = 1.26 |
| Total number of cases: 19,971 | Average RR = 0.98 | Average RR = 0.94 | Average RR = 0.93 | Average RR = 0.89 | ||
| Excluding data from Kinjo Y [10] | Total number of cases: 8.941 | Average RR = 0.97 | Average RR = 0.89 | Average RR = 0.86 | Average RR = 0.86 |
| Author | Cohort name | Cases | Relative Risk among men | Relative Risk among women |
|---|---|---|---|---|
| 42) Larsson SC (2011) | The Swedish Mammography Cohort | 1,680 | - | RR = 0.84 (0.71-0.98; P = 0.049) |
| 36) Iso H (2007) | The JACC Study | 1,230 men, and 1,014 women | HR = 1.00 (0.87-1.16) | HR = 0.87 (0.73-1.02; P = < 0.10) |
| 35) Bravata DM (2007) | No cohort name defined | 369 | HR = 0.89 (0.59-1.36) | - |
| 34) Myint PK (2006) | The EPIC-Norfolk Study | 217 men, and 204 women | RR = 1.34 (0.93-2.93; P = 0.26) | RR = 0.86 (0.60-1.24; P = 0.29) |
| 29) Folsom AR (2004) | The Iowa Women's Health Study | 313 | - | RR = 1.06 (0.67-1.67; P = 0.65) |
| 23) Nagata C (2002) | The Takayama Study | 137 men, and 132 women | HR = 1.19 (0.78-1.81; P = 0.37) | HR = 0.87 (0.58-1.30; P = 0.49) |
| 22) Wennberg M (2007) | The MONICA Study | 189 men, and 128 women | OR = 1.24 (1.01-1.51; P = 0.04) | OR = 0.90 (0.73-1.12; P = 0.35) |
| 19) Yuan JM (2001) | The Shanghai Cohort Study | 480 | RR = 1.05 (0.77-1.43; P = 0.47) | - |
| 17) Gillum RF (1996) | The NHANES I | 262 white men, 251 white women | RR = 0.85 (0.49-1.46) | RR = 0.55 (0.32-0.93; P = 0.05) |
| 15) Morris MC (1995) | The Physician's Health Study | 173 | RR = 0.6 (0.3-1.6; P = 0.13) | - |
| 14) He K (2002) | The Health Professsional's Follow-up Study | 608 | RR = 0.83 (0.53-1.29; P = 0.81) | - |
| 14) Iso H (2001) | The Nurses' Health Study | 574 | - | RR = 0.48 (0.21-1.06; P = 0.06) |
| 6) Lapidus L (1986) | No cohort name defined | 13 | - | No significant association |
| 2) Orencia AJ (1996) | The Western Electric Study | 222 | HR = 1.26 (0.74-2.16) | - |
| 1) Keli SO (1994) | The Zutphen Study | 42 | HR = 0.71 (0.38-1.33) | - |
| Total number of cases: 3,929 men, and 4,309 women | Average RR = 0.99 | Average RR = 0.80 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 35) Bravata DM (2007) | No cohort name defined | 369 | Risk | HR = 0.89 (0.59-1.36) |
| 29) Folsom AR (2004) | The Iowa Women's Health Study | 313 | Mortality | RR = 1.06 (0.67-1.67; P = 0.65) |
| 24) Mozaffarian D (2005) | The Cardiovascular Health Study | 626 | Risk | HR = 0.74 (0.54-1.02; P = 0.04) |
| 17) Gillum RF (1996) | The NHANES I | 262 white men, 251 white women, 107 black men and women | Risk | White men: RR = 0.85 (0.49-1.46). White women: RR = 0.55 (0.32-0.93; P = 0.05). Black men and women: RR = 0.51 (0.30-0.88; P = < 0.05). |
| 15) Morris MC (1995) | The Physician's Health Study | 173 | Risk | RR = 0.6 (0.3-1.6; P = 0.13) |
| 14) He K (2002) | The Health Professsional's Follow-up Study | 608 | Risk | RR = 0.83 (0.53-1.29; P = 0.81) |
| 14) Iso H (2001) | The Nurses' Health Study | 574 | Risk | RR = 0.48 (0.21-1.06; P = 0.06) |
| 2) Orencia AJ (1996) | The Western Electric Study | 222 | Risk | HR = 1.26 (0.74-2.16) |
| Total number of cases: 3,505 | Average RR = 0.77 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 42) Larsson SC (2011) | The Swedish Mammography Cohort | 1,680 | Risk | RR = 0.84 (0.71-0.98; P = 0.049) |
| 34) Myint PK (2006) | The EPIC-Norfolk Study | 217 men, and 204 women | Risk | Men: RR = 1.34 (0.93-2.93; P = 0.26). Women: RR = 0.86 (0.60-1.24; P = 0.29). |
| 31) Ness AR (2005) | The Boyd Orr Cohort | 83 | Mortality | RR = 2.01 (1.09-3.69; P = 0.01) |
| 22) Wennberg M (2007) | The MONICA Study | 189 men, and 128 women | Risk | Men: OR = 1.24 (1.01-1.51; P = 0.04). Women: OR = 0.90 (0.73-1.12; P = 0.35). |
| 13) Montonen J (2009) | The Finnish Mobile Clinic Health Survey | 659 | Risk | RR = 1.01 (0.81-1.27; P = 0.80) |
| 6) Lapidus L (1986) | No cohort name defined | 13 | Risk | No significant association |
| 1) Keli SO (1994) | The Zutphen Study | 42 | Risk | HR = 0.71 (0.38-1.33) |
| Total number of cases: 3,202 | Average RR = 0.96 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 36) Yamagishi K (2008) | The JACC Study | 972 | Mortality | HR = 0.91 (0.74-1.13; P = 0.40) |
| 32) Nakamura Y (2005) | The NIPPON DATA80 | 288 | Mortality | RR = 1.28 (0.71-2.32; P = 0.50) for the highest vs second quintile of consumption |
| 27) Sauvaget C (2003) | The Hiroshima/Nagasaki Life Span Study | 1,462 | Mortality | HR = 0.85 (0.75-0.98; P = 0.02) |
| 23) Nagata C (2002) | The Takayama Study | 137 men, and 132 women | Mortality | Men: HR = 1.19 (0.78-1.81; P = 0.37). Women: HR = 0.87 (0.58-1.30; P = 0.49). |
| 19) Yuan JM (2001) | The Shanghai Cohort Study | 480 | Mortality | RR = 1.05 (0.77-1.43; P = 0.47) |
| 10) Kinjo Y (1999) | No cohort name defined | 11,030 | Mortality | RR = 0.86 (0.79-0.94) |
| Total number of cases: 14,501 | Average RR = 0.87 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 24) Mozaffarian D (2005) | The Cardiovascular Health Study | 537 | Ischemic stroke risk | HR = 0.70 (0.50-0.99; P = 0.02) |
| 14) He K (2002) | The Health Professsional's Follow-up Study | 377 | Ischemic stroke risk | RR = 0.54 (0.31-0.94; P = 0.28) |
| 14) Iso H (2001) | The Nurses' Health Study | 303 | Ischemic stroke risk | RR = 0.38 (0.12-1.19; P = 0.09) |
| Total number of cases: 1,217 | Average RR = 0.57 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 42) Larsson SC (2011) | The Swedish Mammography Cohort | 1,310 | Cerebral infarction risk | RR = 0.87 (0.73-1.04; P = 0.19) |
| 22) Wennberg M (2007) | The MONICA Study | 147 men, and 111 women | Ischemic stroke risk | Men: OR = 1.25 (1.00-1.56; P = 0.04). Women: OR = 0.93 (0.74-1.17; P = 0.51). |
| 13) Montonen J (2009) | The Finnish Mobile Clinic Health Survey | 364 | Thrombosis or embolia risk | RR = 0.99 (0.73-1.35; P = 0.96) |
| Total number of cases: 1,932 | Average RR = 0.92 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 36) Yamagishi K (2008) | The JACC Study | 319 | Ischemic stroke mortality | HR = 0.93 (0.65-1.34; P = 0.78) |
| 32) Nakamura Y (2005) | The NIPPON DATA80 | 165 | Cerebral infarction death | RR = 1.11 (0.50-2.47; P = 0.70) for the highest vs second quintile of consumption |
| 27) Sauvaget C (2003) | The Hiroshima/Nagasaki Life Span Study | 665 | Cerebral infarction mortality | HR = 0.94 (0.77-1.14; P = 0.50) |
| 10) Kinjo Y (1999) | No cohort name defined | 4,084 | Embolism and thrombosis mortality | RR = 0.99 (0.86-1.14) |
| Total number of cases: 5,233 | Average RR = 0.98 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 24) Mozaffarian D (2005) | The Cardiovascular Health Study | 73 | Hemorrhagic stroke risk | HR = 0.93 (0.37-2.33; P = 0.66) |
| 14) He K (2002) | The Health Professsional's Follow-up Study | 106 | Hemorrhagic stroke risk | RR = 1.55 (0.45-5.35; P = 0.70) |
| 14) Iso H (2001) | The Nurses' Health Study | 181 | Hemorrhagic stroke risk | RR = 1.02 (0.34-3.10; P = 0.33) |
| Total number of cases: 360 | Average RR = 1.16 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 42) Larsson S (2011) | The Swedish Mammography Cohort | 233 | Hemorrhagic stroke risk | RR = 0.67 (0.42-1.08; P = 0.08) |
| 22) Wennberg M (2007) | The MONICA Study | 39 men, and 15 women | Hemorrhagic stroke risk | Men: OR = 1.14 (0.69-1.88; P = 0.59). Women: OR = 0.61 (0.23-1.57; P = 0.31). |
| 13) Montonen J (2009) | The Finnish Mobile Clinic Health Survey | 80 | Intracerebral haemorrhage risk | RR = 1.23 (0.63-2.42; P = 0.41) |
| Total number of cases: 367 | Average RR = 0.84 |
| Author | Cohort name | Cases | End point | Relative Risk (RR) |
|---|---|---|---|---|
| 36) Yamagishi K (2008) | The JACC Study | 180 intraparenchymal hemorrhage, and 153 subarachnoid hemorrhage | Mortality | Intraparenchymal hemorrhage: HR = 0.95 (0.62-1.47; P = 0.58). Subarachnoid hemorrhage: HR = 0.96 (0.55-1.68; P = 0.84). |
| 32) Nakamura Y (2005) | The NIPPON DATA80 | 63 | Cerebral hemorrhage death | RR = 0.93 (0.20-4.28; P = 0.97) for the highest vs second quintile of consumption |
| 27) Sauvaget C (2003) | The Hiroshima/Nagasaki Life Span Study | 354 | Intracerebral haemorrhage mortality | HR = 0.70 (0.54-0.92; P = 0.008) |
| 10) Kinjo Y (1999) | No cohort name defined | 4,773 | Cerebral haemorrhage mortality | RR = 0.87 (0.76-0.98) |
| Total number of cases: 5,523 | Average RR = 0.87 |